CGA
MRSN

Crescent Grove Advisors’s Mersana Therapeutics MRSN Stock Holding History

Crescent Grove Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400
Closed -$16K – 166
2019
Q3 		$16K Buy
+400
New +$29.1K ﹤0.01% 153

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Crescent Grove Advisors's MRSN Position: Q4 2019 in Review

Crescent Grove Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2019, closing a stake of 400 shares — an estimated $16K sold.

Crescent Grove Advisors first reported a position in MRSN in Q3 2019 and held it in 1 quarter. The position peaked at $16K in Q3 2019. 69 funds tracked by Wall St. Rank hold MRSN as of Q4 2019.

  • Crescent Grove Advisors reported no remaining Mersana Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Crescent Grove Advisors sold 400 Mersana Therapeutics shares in Q4 2019, an estimated $16K.
  • Crescent Grove Advisors first reported a position in Mersana Therapeutics in Q3 2019 and held it in 1 quarter.
  • Crescent Grove Advisors's Mersana Therapeutics position peaked at $16K in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2019.

Based on Crescent Grove Advisors's 13F filing for Q4 2019, filed 3 Feb 2020.